IQnovate focuses on every segment of the drug life cycle, from preclinical-clinical, through to RRC, bridging science with business.
Our expertise and capabilities are positioned in designing and executing:
Our Biotech Capital Advisory is tailored specifically to cater to the Global Institutional Investment Community. Our objective is to establish the Australian Biotech industry as a critical alternative asset option within the alternative asset class. IQnovate’s global successful track record in identifying investment for the biotech & life science research attracts high quality deal origination and deal flow with significant growth potential creating win-win situations for the investors and the companies.
The corporate vision is not to just survive, but to thrive in these challenging times. We help to transform drug development and commercialization by linking business strategy, scientific expertise and data to deliver unique and impactful bottom line results.
IQnovate occupies a unique space where science is translated into business. A consulting firm can’t offer this kind of strategic insight, a traditional regulatory affairs-market access consultancy or CRO can’t draw upon this level of industry experience.
Our value proposition lies in: